Search research articles
Contact Us
Filters
Showing results (361-370 of 371) with videos related to
Page
of 38
Sort By:
Joint Bone Spine
|
October 19, 2025
Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease
Pierre-Antoine Juge, Marie-Pierre Debray, Valérie Devauchelle Pensec, et al.
Seminars in Arthritis and Rheumatism
|
November 14, 2018
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Jocelyn Quistrebert, Signe Hässler, Delphine Bachelet, et al.
Arthritis and Rheumatism
|
May 28, 2010
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry
Benjamin Terrier, Zahir Amoura, Philippe Ravaud, et al.
RMD Open
|
June 5, 2025
Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies
Marie Robert, Yann Nguyen, Yves Allenbach, et al.
Annals of the Rheumatic Diseases
|
September 24, 2024
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
Bruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, et al.
Joint Bone Spine
|
June 28, 2011
TNF alpha antagonist therapy and safety monitoring
Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 9, 2023
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
Joanna Kedra, Philippe Dieudé, Caroline Giboin, et al.
JAMA
|
September 23, 2016
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
Jacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger, et al.
Annals of the Rheumatic Diseases
|
March 13, 2026
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
Josef S Smolen, Christopher J Edwards, Victoria Konzett, et al.
Annals of the Rheumatic Diseases
|
February 14, 2023
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Pedro M Machado, Martin Schäfer, Satveer K Mahil, et al.
Page
of 38
Search research articles
Search
Showing results (361-370 of 371) with videos related to
Sort By:
Page
of 38
Joint Bone Spine
|
October 19, 2025
Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease
Pierre-Antoine Juge, Marie-Pierre Debray, Valérie Devauchelle Pensec, et al.
Seminars in Arthritis and Rheumatism
|
November 14, 2018
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Jocelyn Quistrebert, Signe Hässler, Delphine Bachelet, et al.
Arthritis and Rheumatism
|
May 28, 2010
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry
Benjamin Terrier, Zahir Amoura, Philippe Ravaud, et al.
RMD Open
|
June 5, 2025
Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies
Marie Robert, Yann Nguyen, Yves Allenbach, et al.
Annals of the Rheumatic Diseases
|
September 24, 2024
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
Bruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, et al.
Joint Bone Spine
|
June 28, 2011
TNF alpha antagonist therapy and safety monitoring
Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 9, 2023
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
Joanna Kedra, Philippe Dieudé, Caroline Giboin, et al.
JAMA
|
September 23, 2016
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
Jacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger, et al.
Annals of the Rheumatic Diseases
|
March 13, 2026
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
Josef S Smolen, Christopher J Edwards, Victoria Konzett, et al.
Annals of the Rheumatic Diseases
|
February 14, 2023
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Pedro M Machado, Martin Schäfer, Satveer K Mahil, et al.
Page
of 38